Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Bevacizumab + Carboplatin + Paclitaxel & Ovarian Cancer, both FDA and EMA have explicit approvals for Bevacizumab + Carboplatin + Paclitaxel for front‑line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, with continued bevacizumab as maintenance (1, 2)
The randomized clinical phase III trial, identified as NCT01802749, demonstrated that continuing bevacizumab beyond progression, when combined with chemotherapy, enhances progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compa…